. 2020 Dec 24;99(4):115294. doi: 10.1016/j.diagmicrobio.2020.115294

Table 2.

Assay characteristics of the surrogate virus neutralization test (sVNT) for SARS-CoV-2 PRNT-50 positives and PRNT-90 positives.

	sVNT vs PRNT-50	sVNT vs PRNT-90
Sensitivity	89.8% (141/157; 84.0%–94.1%)	99.0%^⁎⁎ (97/98; 94.5%–100%, P< 0.0001)
False negative rate	10.2% (16/157; 5.94%–16.0%)	1.02%^⁎⁎ (1/98; 0.02%–5.56%; P< 0.0001)
Non-neutralizing antibody detection rate^a	32.4% (12/37; 18.0%–49.8%)	58.3%^* (56/96; 47.8%–68.3%, P= 0.0014)
Specificity	100% (47/47; 92.5%–100%)	100% (47/47; 92.5%–100%)

Sensitivity: percentage of SARS-CoV-2 PRNT positive samples from COVID-19 patients that also tested positive by sVNT. False negative rate: percentage of SARS-CoV-2 PRNT positive samples from COVID-19 patients, which tested negative by sVNT.

Non-neutralizing antibody detection rate: percentage of SARS-CoV-2 PRNT negative samples from COVID-19 patients, which tested positive by sVNT. Specificity: percentage of SARS-CoV-2 PRNT negative samples from healthy individuals that also tested negative by sVNT. Pearson's Chi-square tests were conducted to analyze the difference in sensitivity of the sVNT for PRNT-50+ and PRNT-90+ COVID-19 specimens. Number of specimens of total subset and 95% confidence intervals are indicated in parentheses.

^⁎

P < 0.05.

^⁎⁎

P < 0.0001.